Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1959 1
1961 3
1964 4
1965 1
1966 1
1967 2
1968 1
1970 1
1971 2
1972 3
1973 3
1974 7
1975 52
1976 55
1977 60
1978 65
1979 133
1980 141
1981 158
1982 125
1983 123
1984 128
1985 131
1986 133
1987 164
1988 197
1989 228
1990 254
1991 249
1992 352
1993 355
1994 439
1995 449
1996 511
1997 625
1998 715
1999 827
2000 870
2001 953
2002 1158
2003 1332
2004 1525
2005 1843
2006 2022
2007 2196
2008 2573
2009 2952
2010 3253
2011 3728
2012 4304
2013 4967
2014 5755
2015 6165
2016 4844
2017 4354
2018 5670
2019 6229
2020 7339
2021 8345
2022 9173
2023 8977
2024 3531

Text availability

Article attribute

Article type

Publication date

Search Results

99,314 results

Results by year

Filters applied: . Clear all
Page 1
An Immunological Hypothesis of Fu's Subcutaneous Needling Acupuncture.
Xu W, Wu J, Xu P. Xu W, et al. J Acupunct Meridian Stud. 2021 Jun 30;14(3):110-115. doi: 10.51507/j.jams.2021.14.3.110. J Acupunct Meridian Stud. 2021. PMID: 35770566
Fu's subcutaneous needling (FSN) is a novel acupuncture approach. ...The theoretical inference indicates that FSN treatment may affect the body's immune system through subcutaneous connective tissue, similar to triggering a cobweb-like system. ...
Fu's subcutaneous needling (FSN) is a novel acupuncture approach. ...The theoretical inference indicates that FSN treatment ma …
[Distinguishment of XU Qiu-fu's thirteen ghost points].
Xiong RH, Zhang SJ. Xiong RH, et al. Zhongguo Zhen Jiu. 2023 Jun 12;43(6):709-14. doi: 10.13703/j.0255-2930.20220504-k0006. Zhongguo Zhen Jiu. 2023. PMID: 37313567 Chinese.
In addition to the well-known thirteen ghost points in Qianjin Fang (Important Formulas worth a Thousand Gold Pieces), "XU Qiu-fu's thirteen ghost points" is recorded in other medical books. The contents of "XU Qiu-fu's thirteen ghost points" are not e …
In addition to the well-known thirteen ghost points in Qianjin Fang (Important Formulas worth a Thousand Gold Pieces), "XU Qiu-fu' …
[Revelation of Fu's subcutaneous needling therapy on the development of acupuncture and moxibustion].
Lin Q, Luo NS, Yang CY, Fan XY, Wang Y, Zhou WZ, Fan GQ. Lin Q, et al. Zhongguo Zhen Jiu. 2020 Mar 12;40(3):307-14. doi: 10.13703/j.0255-2930.20190223-k0005. Zhongguo Zhen Jiu. 2020. PMID: 32270647 Chinese.
By analyzing Fu 's subcutaneous needling phenomenon, the attribute of Fu 's subcutaneous needling therapy in traditional acupuncture, the innovation and the role in the development of traditional acupuncture were demonstrated. ...The needle device and …
By analyzing Fu 's subcutaneous needling phenomenon, the attribute of Fu 's subcutaneous needling therapy in tra …
[Therapeutic observation on Fu's acupuncture for cervical spondylosis of vertebral artery type based on Tongtuo method].
Zheng H, Zhang JM, Wu XT, Xie J. Zheng H, et al. Zhongguo Zhen Jiu. 2021 Dec 12;41(12):1313-6. doi: 10.13703/j.0255-2930.20201113-0002. Zhongguo Zhen Jiu. 2021. PMID: 34936266 Clinical Trial. Chinese.
OBJECTIVE: To verify the superiority of Fu's acupuncture for cervical spondylosis of vertebral artery type (CSA) based on Cheng's Tongtuo method. METHODS: A total of 150 patients with CSA were randomly divided into a Tongtuo Fu's acupuncture gro …
OBJECTIVE: To verify the superiority of Fu's acupuncture for cervical spondylosis of vertebral artery type (CSA) based on Chen …
S-1 (Teysuno): a review of its use in advanced gastric cancer in non-Asian populations.
Sanford M. Sanford M. Drugs. 2013 Jun;73(8):845-55. doi: 10.1007/s40265-013-0062-y. Drugs. 2013. PMID: 23719766 Review.
S-1 (Teysuno()) is an oral anticancer agent comprising the 5-fluorouracil (5-FU) prodrug tegafur and targeted modulators, gimeracil and oteracil. ...S-1 is a useful alternative to 5-FU for patients with advanced gastric cancer....
S-1 (Teysuno()) is an oral anticancer agent comprising the 5-fluorouracil (5-FU) prodrug tegafur and targeted modulators, gime …
S-1 as a core anticancer fluoropyrimidine agent.
Miura K, Shirasaka T, Yamaue H, Sasaki I. Miura K, et al. Expert Opin Drug Deliv. 2012 Mar;9(3):273-86. doi: 10.1517/17425247.2012.652945. Epub 2012 Jan 11. Expert Opin Drug Deliv. 2012. PMID: 22235991 Review.
Orally administrable fluoropyrimidine prodrugs have been developed to enhance the anticancer efficacy of 5-FU and to reduce its adverse reactions. AREAS COVERED: S-1 is an FT-based oral 5-FU prodrug in combination with a DPD inhibitor (CDHP) and an OPRT inhib …
Orally administrable fluoropyrimidine prodrugs have been developed to enhance the anticancer efficacy of 5-FU and to reduce its adver …
[Guiding significance of "disease-syndrome-symptom" mode in FU Qing-zhu's Obstetrics and Gynecology (FU Qing-zhu Nyu Ke) for dealing with ovulation disorder infertility caused by hyperprolactinemia].
Liu XQ, Ma K, Zhang XY, Yin YD. Liu XQ, et al. Zhongguo Zhong Yao Za Zhi. 2022 Mar;47(6):1694-1699. doi: 10.19540/j.cnki.cjcmm.20211208.502. Zhongguo Zhong Yao Za Zhi. 2022. PMID: 35347969 Chinese.
This paper discussed the guiding significance of "disease-syndrome-symptom" mode in FU Qing-zhu's Obstetrics and Gynecology(FU Qing-zhu Nyu Ke) for dealing with ovulation disorder infertility caused by hyperprolactinemia(HPRL). FU Qin …
This paper discussed the guiding significance of "disease-syndrome-symptom" mode in FU Qing-zhu's Obstetrics …
KLF4 targets RAB26 and decreases 5-FU resistance through inhibiting autophagy in colon cancer.
Zheng Y, Wu J, Chen H, Lin D, Chen H, Zheng J, Xia H, Huang L, Zeng C. Zheng Y, et al. Cancer Biol Ther. 2023 Dec 31;24(1):2226353. doi: 10.1080/15384047.2023.2226353. Cancer Biol Ther. 2023. PMID: 37431852 Free PMC article.
BACKGROUND: Accumulating studies demonstrated that resistance of colon cancer (CC) to 5-fluorouracil (5-FU) contributes to adverse prognosis. We investigated how Kruppel-like factor 4 (KLF4) affected 5-FU resistance and autophagy in CC cells. ...Autophagy activator …
BACKGROUND: Accumulating studies demonstrated that resistance of colon cancer (CC) to 5-fluorouracil (5-FU) contributes to adverse pr …
[Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept].
Shirasaka T, Taguchi T. Shirasaka T, et al. Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:4-18. Gan To Kagaku Ryoho. 2006. PMID: 16897967 Review. Japanese.
Consequently, we concretized an innovative therapeutic drug, TS-1 (S-1). We have a long history of research before developing S-1, which is represented by a series of investigations consisting in the developments of Futrafur (FT)--an oral anticancer agent of a 5- …
Consequently, we concretized an innovative therapeutic drug, TS-1 (S-1). We have a long history of research before developing S …
[Combination therapy of continuous venous infusion (CVI) of 5-FU and low dose consecutive cisplatin (CDDP), and the new oral anti-cancer drug S-1 for advanced gastro-intestinal cancer].
Shirasaka T, Aiba K, Araki H, Suzuki M, Terashima M, Mikami Y. Shirasaka T, et al. Gan To Kagaku Ryoho. 1999 Mar;26(4):456-66. Gan To Kagaku Ryoho. 1999. PMID: 10097742 Review. Japanese.
S-1 is a newly developed oral anti-cancer drug which is a combination of Tegafur (FT), a prodrug of 5-FU and two modulators (CDHP, an inhibitor of 5-FU degradation and Oxo, a selective inhibitor GI toxicity by 5-FU) at a molar ratio of 1:0.4:1. ...In t …
S-1 is a newly developed oral anti-cancer drug which is a combination of Tegafur (FT), a prodrug of 5-FU and two modulators (C …
99,314 results
You have reached the last available page of results. Please see the User Guide for more information.